TB-500 Australia: Complete Research Guide
For laboratory research use only. Not for human use. Research use only.
TB-500 is the synthetic form of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid peptide found in virtually all human and animal cells. It has been studied extensively in preclinical models for its apparent role in actin regulation, tissue repair, angiogenesis, and inflammation modulation. This guide covers the research landscape for Australian researchers.
What is TB-500?
TB-500 is a synthetic peptide corresponding to the active region of Thymosin Beta-4 (amino acids 17-23: Ac-LKKTETQ). Thymosin Beta-4 is one of the most abundant peptides in mammalian cells and plays a critical role in actin sequestration and cytoskeletal organisation.
TB-500 has been studied in preclinical models for its apparent effects on wound healing, muscle repair, tendon regeneration, and cardiac tissue recovery. It is not approved by the TGA for human use and is available in Australia for laboratory research use only.
Mechanism of Action
TB-500's primary mechanism involves binding to G-actin (monomeric actin) and preventing its polymerisation into F-actin (filamentous actin). This actin sequestration activity is thought to facilitate cell migration — a critical process in tissue repair and wound healing.
Research has also identified TB-500's apparent role in upregulating cell surface receptors involved in angiogenesis, including VEGF receptors. Preclinical studies have observed increased blood vessel formation in wound models treated with TB-500, which may contribute to the observed tissue repair effects.
Preclinical Research Findings
In rodent models, researchers have observed apparent acceleration of wound closure, tendon repair, and muscle regeneration following TB-500 administration. A 2010 study in the Journal of Cardiovascular Pharmacology examined TB-500's apparent cardioprotective effects in a myocardial infarction model, observing reduced infarct size and improved cardiac function.
TB-500 is frequently studied in combination with BPC-157 in preclinical tissue repair models. The two peptides are thought to act through complementary mechanisms — BPC-157 primarily through the nitric oxide pathway and TB-500 through actin regulation — potentially producing additive effects in tissue repair research.
Research Supply in Australia
PeptideIQ supplies research-grade TB-500 in Australia at ≥98% purity, verified by third-party HPLC testing. Available in lyophilised powder form with full Certificate of Analysis. Express delivery Australia-wide.
Frequently Asked Questions
What is the difference between TB-500 and Thymosin Beta-4?
Thymosin Beta-4 is the full 43-amino acid naturally occurring peptide. TB-500 is a synthetic peptide corresponding to the active region (amino acids 17-23) of Thymosin Beta-4. TB-500 is more stable and easier to synthesise than the full Tβ4 sequence.
Can TB-500 and BPC-157 be studied together?
Yes, preclinical research has examined the combination of TB-500 and BPC-157 in tissue repair models. The two peptides are thought to act through complementary mechanisms. For laboratory research use only.
Disclaimer: All products supplied by PeptideIQ are for laboratory research use only. They are not approved for human use, consumption, or therapeutic application. PeptideIQ complies with all applicable Australian regulations including the Therapeutic Goods Act 1989.